EPAC1 Activators Restore Artery Function Damaged by Vascular Inflammation
New selective EPAC1 activators reverse IL-6-driven endothelial dysfunction and curb cellular overgrowth in arteries, opening a therapeutic path for atherosclerosis.
Summary
Researchers identified EPAC1, a cAMP-sensing protein, as a key regulator of vascular inflammation in atherosclerosis. Using single-cell RNA sequencing, they confirmed EPAC1 is concentrated in endothelial cells lining arteries, with elevated expression in diseased vessels. In laboratory models, the inflammatory signal IL-6 impaired the artery's ability to relax via nitric oxide — a hallmark of endothelial dysfunction. Treatment with selective EPAC1 activators (SY007, D-007, PWO577) restored this relaxation response, suppressed inflammatory gene expression, increased eNOS levels, and reduced abnormal cell outgrowth driven by vascular injury. Mice lacking EPAC1 showed worsened cellular overgrowth, confirming the protein's protective role. These findings position targeted EPAC1 activation as a promising strategy to combat cardiovascular disease.
Detailed Summary
Atherosclerosis — the buildup of plaques in artery walls — is driven in large part by chronic vascular inflammation that damages the inner lining of blood vessels, called the endothelium. When endothelial cells malfunction, arteries lose their ability to regulate blood flow, setting the stage for heart attack and stroke. Identifying molecular targets that can restore endothelial health is a major priority in cardiovascular medicine.
This study focused on EPAC1, a protein activated by the signaling molecule cyclic AMP (cAMP). The researchers used single-cell RNA sequencing to map where EPAC1 is expressed in both healthy and atherosclerotic mouse aortae and confirmed its elevated presence in the endothelial cells of diseased human coronary arteries — suggesting it plays an active role in the disease process.
Using isolated aortic ring preparations, the team showed that exposing vessels to IL-6 and its soluble receptor significantly impaired acetylcholine-induced, nitric oxide-mediated relaxation — a standard measure of endothelial function. Three selective EPAC1 activators (SY007, D-007, and PWO577) effectively reversed this impairment. In a vascular injury model, IL-6 triggered excessive cellular outgrowth from aortic rings, mimicking pathological remodeling; EPAC1 activators curtailed this growth, while EPAC1 knockout mice displayed exaggerated outgrowth, confirming EPAC1's restraining role.
In a human three-cell co-culture system (endothelial cells, smooth muscle cells, macrophages), EPAC1 activators drove transcriptional changes that increased eNOS expression and suppressed pro-inflammatory mediators, suggesting broad endothelial reprogramming toward a healthier state.
While results are compelling, the study is preclinical. All models are in vitro or ex vivo, and efficacy and safety in living organisms with established atherosclerosis remain to be demonstrated. Still, selective EPAC1 activation represents a mechanistically grounded and potentially druggable approach to vascular disease.
Key Findings
- EPAC1 is enriched in endothelial cells of atherosclerotic mouse and human arteries, implying a disease-relevant role.
- Selective EPAC1 activators restored IL-6-impaired nitric oxide-mediated artery relaxation in ex vivo aortic rings.
- EPAC1 activation reduced IL-6-driven vascular cell outgrowth; EPAC1 knockout mice showed the opposite effect.
- In a tri-cell co-culture, EPAC1 activators upregulated eNOS and downregulated pro-inflammatory gene expression.
- EPAC1 suppresses inflammation via SOCS3 upregulation and JAK/STAT3 pathway inhibition.
Methodology
The study combined single-cell RNA sequencing of murine and human arterial tissue with ex vivo aortic ring functional assays and a human three-cell co-culture model. EPAC1 knockout mice were used to confirm gene-specific effects on vascular remodeling.
Study Limitations
All experiments are preclinical, using in vitro cell cultures, ex vivo tissue models, and knockout mice — not intact living animal disease models. Long-term safety, bioavailability, and efficacy of EPAC1 activators in vivo with established atherosclerosis are not yet established. The full spectrum of off-target effects of the activator compounds requires further characterization.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: